Home Companies Catalysts Deep Dives
Tafinlar + Mekinist dabrafenib + trametinib APPROVED
Drug Profile
ModalitySmall molecule
RouteOral
Therapy AreaOncology
Launch2013-05-29
US LOE2028-05-01
Peak Sales Est$1800M
Formulations[{"id":"tafinlar-oral","doses":"Tafinlar 75mg, 50mg capsules","route":"Oral","setting":"PATIENT_SELF
Companies
NVS (ORIGINATOR)100%
Mechanism: BRAF + MEK inhibitor combination
Expert: Combined inhibition of BRAF V600 and MEK1/2 in the MAPK pathway
Everyday: Blocks two proteins in the same cancer pathway for better results
Targets: ["BRAF","MEK"]
Revenue History
PeriodRevenue ($M)
2024$1,420M
2025$1,350M
Programs (2)
IndicationStageKey StudyRegional Status
BRAF+ MelanomaAPPROVEDCOMBI-d/v[{"stage":"APPROVED","region":"US","approval_date":"2014-01-10"},{"stage":"APPRO
BRAF+ NSCLCAPPROVEDBRF113928[{"stage":"APPROVED","region":"US","approval_date":"2017-06-22"}]
Notes
BRAF/MEK combination. Melanoma and NSCLC. Originally GSK.
Data from Supabase · Updated 2026-03-24